"Pricing transparency reports ... Continued assessment of direct-to-consumer advertising requirements ... Reduce backlog of generic applications ... Foster competition for branded drugs ... Target exclusivity protections to truly innovative products ... Increase oversight of 'pay for delay' settlements ... Shorten the exclusivity period for biologics and promote policies to increase the uptake of biosimilars ... Expand research on treatment effectiveness and value ... [Require] drug manufacturers ... to conduct comparisons of new products to existing products ... Expand the availability of value -- based pricing."